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Accelerated renal function decline in obese post myocardial infarction patients -is weight reduction per se an adequate therapeutic consequence?
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As compared with normal weight patients (defined as a BMI of 18.5-24.9 kg/m 2 ), obese women and men at baseline presented with a slightly but significantly lower cystatin C based estimated glomerular filtration rate (eGFRcysC). Moreover, the subsequent annual decline in eGFRcysC was significantly increased, by 45% in obese women and by 30% in obese men. Extrapolating this decline to a follow-up period of 10 years most obese patients of this medically well supervised cohort would have reached a clinically relevant reduction of kidney function ending with a eGFRcysC of 58.2 ml/min per 1.73 m 3 in obese women and 63.1 ml/min per 1.73 m 3 in obese men. Moreover, it appears to be obvious that the eGFRcysC decline observed in the 'Alpha Omega' population may even be aggravated in populations being less well medically controlled and/or presenting with a history of obesity over several decades. The question therefore is whether the long-term negative effect of obesity on kidney function is a potentially reversible process and targeted interventions are effective in preventing obesity related acceleration of kidney function decline. The consequent and individualized adjustment to a healthy lifestyle certainly represents a baseline requirement in this context. Therefore 'weight reduction', 'healthy diet' and 'physical exercise' are discussed in more detail.
Weight reduction
The Alpha Omega Cohort Study was not designed to evaluate the effect of weight reduction on kidney function, and BMI did not significantly change during follow-up in this study. However, apart from some selected patients in whom bariatric surgery may be considered as a therapeutic option, 3 weight reduction per se -as measured by reduction of BMI or waist circumference -may not be a sufficiently characterized goal to preserve or regain appropriate renal function. In line with this, a recent consensus report of renal dietitians did not recommend medical or surgical strategies to facilitate weight reduction in isolation. 4 Kidney function should be considered within the close interactive network of organs, especially the cardiovascular system and metabolism. A healthy cardiovascular system and a balanced metabolism are prerequisites for a normal renal function, thereby highlighting additional healthrelated interventions that surpass the potential goal of weight reduction alone. These interventions include the adoption of healthy diet and regular physical exercise.
Adoption of healthy diet
There is increasing evidence that healthy food intake like the Mediterranean diet (increased intake of fruits, vegetables, legumes, fish and whole grains, and restricted intake of red meat, sodium and sugar) is associated with a significantly improved cardiovascular prognosis including total death. [5] [6] [7] [8] This especially is true for patients with high cardiovascular risk but also has been demonstrated in patients with kidney disease, and a healthy diet has been shown to reduce incidence and progression of chronic kidney disease in patients with type 2 diabetes.
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Physical exercise and exercise tolerance
Another perhaps even more important intervention to ameliorate the negative effects of obesity is the adoption of regular physical exercise.
14 Physically fit overweight or obese persons do have a mortality risk similar to physically fit individuals with normal weight. 15 Therefore, the positive effect of physical fitness on long-term survival beats the negative effect of a high BMI, thereby at least partly explaining the so called 'obesity paradox' in patients with cardiovascular disease, including patients with systolic heart failure. 16, 17 Finally, physical activity was associated with a significantly decreased risk of early chronic kidney disease in patients with type 2 diabetes mellitus without macroalbuminuria. 18 Patients with advanced chronic kidney disease are at special risk for sedentary lifestyle and physical inactivity, thereby inducing a vicious circle of muscle wasting, deconditioning, disability and increased cardiovascular risk, which urgently needs to be interrupted and prevented already at the early stages of the disease. 19, 20 Clinical data support the positive effects of exercise training in chronic kidney disease patients, but its consequent translation into clinical practice must be improved and further research in this field is certainly needed.
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Conclusions
The results of the Alpha Omega Cohort Study presented in this issue strongly support earlier observations of obesity being positively associated with higher risk of incident chronic kidney disease. However, the consequence of this observation may not be to simply apply overall weight reduction rather than start comprehensive lifestyle changes including healthy diet and regular exercise training. This approach evidently reduces cardiovascular risk, and in addition may have the potential to ameliorate or retard adverse characteristics of advanced renal failure such as chronic inflammation, advanced catabolism, protein and muscle wasting. 24 
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